论文部分内容阅读
１２名健康志愿者，随机交叉口服单剂量（２００ｍｇ）国产司巴沙星胶囊和国外司巴沙星片，采用ＨＰＬＣ测得血浆中药物浓度分别在５．２８±１．８３，５．５６±２．３４ｈ达到峰值７１１．７±１１６．３，７５１．８±９５．９ｎｇ／ｍｌ。两种制剂的消除相半衰期分别为１４．１±４．９４，１５．２±２．１５ｈ；血药曲线下面积分别为２０５７６．９±４３９５．４，２１３７８７±３８８４２ｎｇ·ｈ／ｍｌ。药时曲线符合一级吸收的一室模型。以国外片为标准，算得国产司巴沙星胶囊的相对生物利用度为９６．１±１０．４％，经双单侧ｔ检验，两种制剂具有生物等效性。
Twelve healthy volunteers were randomized to receive a single dose (200 mg) of domestic sparfloxacin capsules and sparfloxacin tablets at a randomized crossover level. The plasma concentrations of the drugs were 5.28 ± 1.83 and 5.56 ± 2.34 h reached a peak of 711.7 ± 116.3, 751.8 ± 95.9 ng / ml. The elimination phase half-lives of the two preparations were 14.1 ± 4.94 and 15.2 ± 2.15 h, respectively; the areas under the blood drug profile were 20576.9 ± 4395.4 and 21.3787 ± 3884.2 ng · h / ml. Pharmacokinetic curve in line with the absorption of a one-compartment model. The relative bioavailability of domestic sparfloxacin capsules was 96.1 ± 10.4% based on foreign tablets, and the bioavailability of the two preparations was bioequivalent.